$1.95
0.02[1.04%]
At close: Apr 24
$1.95
0[0.00%]
After Hours: 4:25PM EDT
Cognition Therapeutics
(NASDAQ:CGTX)Cognition Therapeutics Stock (NASDAQ:CGTX), Analyst Ratings, Price Targets, Predictions
Cognition Therapeutics Inc has a consensus price target of $8, established from looking at the 8 latest analyst ratings. The last 3 analyst ratings were released from B. Riley Securities, Oppenheimer, and Ladenburg Thalmann on March 28, 2024, March 27, 2024, and August 14, 2023. With an average price target of $6.67 between B. Riley Securities, Oppenheimer, and Ladenburg Thalmann, there's an implied 241.88% upside for Cognition Therapeutics Inc from these 3 analyst ratings.
Analyst Firms Making Recommendations1
B. Riley Securities
Oppenheimer
Ladenburg Thalmann
Cantor Fitzgerald
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for Cognition Therapeutics
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 03/28/2024 | CGTX | Buy Now | Cognition Therapeutics | $1.95 | 156.41% | B. Riley Securities | Mayank Mamtani | → $5 | Reiterates | Buy → Buy | Get Alert |
| 03/27/2024 | CGTX | Buy Now | Cognition Therapeutics | $1.95 | 361.54% | Oppenheimer | Jay Olson | $9 → $9 | Maintains | Outperform | Get Alert |
| 08/14/2023 | CGTX | Buy Now | Cognition Therapeutics | $1.95 | 207.69% | Ladenburg Thalmann | Aydin Huseynov | $10 → $6 | Maintains | Buy | Get Alert |
| 05/09/2023 | CGTX | Buy Now | Cognition Therapeutics | $1.95 | 361.54% | Oppenheimer | Jay Olson | → $9 | Reiterates | → Outperform | Get Alert |
| 03/24/2023 | CGTX | Buy Now | Cognition Therapeutics | $1.95 | 361.54% | Oppenheimer | Jay Olson | → $9 | Reiterates | → Outperform | Get Alert |
| 09/29/2022 | CGTX | Buy Now | Cognition Therapeutics | $1.95 | 515.38% | Cantor Fitzgerald | Charles Duncan | → $12 | Initiates | → Overweight | Get Alert |
| 04/22/2022 | CGTX | Buy Now | Cognition Therapeutics | $1.95 | 412.82% | Ladenburg Thalmann | Aydin Huseynov | → $10 | Initiates | → Buy | Get Alert |
| 11/03/2021 | CGTX | Buy Now | Cognition Therapeutics | $1.95 | 1028.21% | Oppenheimer | Jay Olson | — | Initiates | → Outperform | Get Alert |
FAQ
What is the target price for Cognition Therapeutics (CGTX)?
The latest price target for Cognition Therapeutics (NASDAQ: CGTX) was reported by B. Riley Securities on March 28, 2024. The analyst firm set a price target for $5.00 expecting CGTX to rise to within 12 months (a possible 156.41% upside). 4 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Cognition Therapeutics (CGTX)?
The latest analyst rating for Cognition Therapeutics (NASDAQ: CGTX) was provided by B. Riley Securities, and Cognition Therapeutics reiterated their buy rating.
When was the last upgrade for Cognition Therapeutics (CGTX)?
There is no last upgrade for Cognition Therapeutics.
When was the last downgrade for Cognition Therapeutics (CGTX)?
There is no last downgrade for Cognition Therapeutics.
When is the next analyst rating going to be posted or updated for Cognition Therapeutics (CGTX)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Cognition Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Cognition Therapeutics was filed on March 28, 2024 so you should expect the next rating to be made available sometime around March 28, 2025.
Is the Analyst Rating Cognition Therapeutics (CGTX) correct?
While ratings are subjective and will change, the latest Cognition Therapeutics (CGTX) rating was a reiterated with a price target of $0.00 to $5.00. The current price Cognition Therapeutics (CGTX) is trading at is $1.95, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.